Environmental or self-antigens and homotypic interactions cause BCR and Toll-like receptor (TLR) signaling, amplifying the response of CLL cells to other alerts through the microenvironment and escalating the activation of anti-apoptotic and proliferation pathways.Duvelisib was the second PI3K inhibitor authorised because of the FDA, also depending